Clinical and histological features of idiosyncratic liver injury: Dilemma in diagnosis of autoimmune hepatitis

Hepatology Research

Volumn 46, Issue 4, 2016, Pages 277-291

  Kuzu, Ufuk Bariş ^a   Öztaş, Erkin ^a   Turhan, Nesrin ^b   Saygili, Fatih ^a   Suna, Nuretdin ^a   Yildiz, Hakan ^a   Kaplan, Mustafa ^a   Akpinar, Muhammet Yener ^a   Akdoğan, Meral ^a   Kaçar, Sabite ^a   Kiliç, Zeki Mesut Yalin ^a   Köksal, Aydin Şeref ^a   Ödemiş, Bülent ^a   Kayaçetin, Ertuğrul ^a  

^a Gastroenterology Department   (Turkey)

^b TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

Autoimmune hepatitis; Clinical and histological features; Drug induced liver injury

Indexed keywords

ALBENDAZOLE; ALKALOID; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; AZATHIOPRINE; BILIRUBIN; CANNABINOID; CEFUROXIME AXETIL; CHROMIUM PICOLINATE; CIPROFLOXACIN; CLARITHROMYCIN; DICLOFENAC; HERBACEOUS AGENT; ISONIAZID; ISOTRETINOIN; METRONIDAZOLE; MONTELUKAST; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORNIDAZOLE; PARACETAMOL; RIFAMPICIN; SILDENAFIL; STEROID; TERBINAFINE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG INDUCED AUTOIMMUNE HEPATITIS; EMPERIPOLESIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IDIOSYNCRATIC DRUG INDUCED LIVER INJURY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ROSETTE FORMATION; TOXIC HEPATITIS;

EID: 84929774438     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12530     Document Type: Article

References (69)

1. Abboud G, Kaplowitz N. Drug-induced liver injury. Drug Saf 2007 30(4): 277-94.
2. Suk KT, Kim DJ. Drug-induced liver injury: present and future. Clin Mol Hepatol 2012 18(3): 249-57.
3. (NIOSH) NIfOSaH. Pocket guide to chemical hazards. Pittsburgh, PAGovernment Printing Office, 2005.
4. Reuben A, Koch DG, Lee WM. The Acute Liver Failure Study Group. Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study. Hepatology 2010 52(6): 2065-76.
5. Lasser KE, Allen PD, Woolhandler SJ et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002 (May 1); 287 (17): 2215-20.
6. Chang CY, Schiano TD. Review article: drug hepatoxicity. Aliment Pharmacol Ther 2007 (May15); 25 (10): 1135-51.
7. Ostapowicz G, Fontana RJ, Schiodt FV et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002 (Dec 17); 137 (12): 947-54.
8. Watkins PB, Seeff LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006 43(3): 618-31.
9. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc 2014 89(1): 95-106.
10. Liu ZX, Kaplowitz N. Immune-mediated drug-induced liver disease. Clin Liver Dis 2002 6(3): 755-74.
11. Björnsson E, Talwalkar J, Treeprasertsuk S et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010 51(6): 2040-8.
12. Germano V, Picchianti Diamanti A, Baccano G et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005 64(10): 1519-20.
13. Pelli N, Setti M. Atorvastatin as a trigger of autoimmune hepatitis. J Hepatol 2004 40(4): 716.
14. Manns MP, Czaja AJ, Gorham JD et al. American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 2010 51(6): 2193-213.
15. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990 11(2): 272-6.
16. Danan G, Benichou C. Causality assessment of adverse reactions to drugseI. A novel method based on the conclusions of international consensus meetings: application to drug induced liver injuries. J Clin Epidemiol 1993 46(11): 1323-30.
17. Alvarez F, Berg PA, Bianchi FB et al. International autoimmune hepatitis group report; review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999 31(5): 929-38.
18. Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis 2009 29(4): 364-72.
19. Ishak KG, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitits. J Hepatol 1995 22(6): 696-9.
20. Okano N, Yamamoto K, Sakaguchi K et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatol Res 2003 (Mar); 25 (3): 263-70.
21. Hennes EM, Zeniya M, Czaja AJ et al. International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008 48(1): 169-76.
22. de Abajo FJ, Montero D, Madurga M et al. Acute and clinically relevant drug-induced liver injury: a population based case-control study . Br J Clin Pharmacol 2004; 58 (1): 71-80.
23. Sgro C, Clinard F, Ouazir K et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002 36(2): 451-5.
24. Andrade RJ, Lucena MI, Fernández MC et al. Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005 129(2): 512-21.
25. Hou FQ, Zeng Z, Wang GQ. Hospital admissions for drug-induced liver injury: clinical features, therapy, and outcomes. Cell Biochem Biophys 2012 64(2): 77-83.
26. Wei G, Bergquist A, Broomé U et al. Acute liver failure in Sweden: etiology and outcome. J Intern Med 2007 262(3): 393-401.
27. Farrell GC. Liver disease caused by drugs, anesthetics, and toxins. In: Feldman M, Friedman LS, Sleisenger MH, eds. Gastrointenstinal and liver disease, 7th edn. : PhiladelphiaWB Saunders, 2002; 1403-47.
28. Chalasani N, Fontana RJ, Bonkovsky HL et al. Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008 135(6): 1924-34.
29. Idilman R, Bektas M, Cinar K et al. The characteristics and clinical outcome of drug-induced liver injury: a single-center experience. J Clin Gastroenterol 2010 44(6): e128-32.
30. Dağ MS, Aydinli M, Oztürk ZA et al. Drug- and herb-induced liver injury: a case series from a single center. Turk J Gastroenterol 2014 25(1): 41-5.
31. Devarbhavi H, Dierkhising R, Kremers WK et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010 105(11): 2396-404.
32. Meier Y, Cavallaro M, Roos M et al. Incidence of drug-induced liver injury in medical inpatients. Eur J Clin Pharmacol 2005 61(2): 135-43.
33. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug induced liver disease. Hepatology 2005 42(2): 481-9.
34. Andrade RJ, Lucena MI, Alonso A et al. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 2004 39(6): 1603-12.
35. O'Donnell JT, Marks DH, Danese P, O'Donnell JJ. Drug-induced liver disease: primer for the primary care physician. Dis Mon 2014 60(2): 55-104.
36. Shapiro MA, Lewis JH. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 2007 11(3): 477-505.
37. Satman I, Omer B, Tutuncu Y et al. TURDEP-II Study Group. Twelve-year trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults. Eur J Epidemiol 2013; 28(2): 169-80.
38. Xiao QH, Deng ZZ, Liu JX et al. Risk factor analysis of hepatic toxicity of antituberculosis agents. Chin J Antibiot 2004 29: 760-1.
39. Björnsson E, Kalaitzakis E, Av Klinteberg V, Alem N, Olsson R. Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol Ther 2007 (Jul 1); 26 (1): 79-85.
40. Andrade RJ, Lucena MI, Kaplowitz N et al. Outcome of acute idiosyncratic druginduced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology 2006 44(6): 1581-8.
41. Dienstag J. Toxic and drug-induced hepatitis. In: Longo D, Fauci A, Kasper DL et al., eds. Harrison's principles of internal medicine, 18th edn. : New YorkMcGraw-Hill, 2011.
42. Nathwani RA, Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis 2006 10(2): 207-17.
43. European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 2009 51(2): 237-67.
44. Czaja A. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011 56(4): 958-76.
45. Giannattasio A, D'Ambrosi M, Volpicelli M, Iorio R. Steroid therapy for a case of severe drug-induced cholestasis. Ann Pharmacother 2006 40(6): 1196-9.
46. Wree A, Dechêne A, Herzer K et al. Steroid and ursodesoxycholic Acid combination therapy in severe drug-induced liver injury. Digestion 2011 84(1): 54-9.
47. Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. Practice Parameters Committee of the American College of Gastroenterology. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014 109(7): 950-67.
48. Kleiner DE, Chalasani NP, Lee W et al. Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014 59(2): 661-70.
49. Wanless IR. Vascular disorders. In: Burt AD, Portmann BC, eds. Pathology of the liver, 5th edn. : ChinaChurchill Livingstone Elseiver, 2007; 613-48.
50. Kasper HU, Drebber U, Hirsch I, Dienes HP. Morphology of drug induced liver damage. Pathologe 2006 27(3): 175-81.
51. Robin MA, Le Roy M, Descatoire V et al. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997 26(1): 2330.
52. Tujios S, Fontana RJ. Mechanisms of drug-induced liver injury: From bedside to bench. Nat Rev Gastroenterol Hepatol 2011 8(4): 202-11.
53. Gough A, Chapman S, Wagstaff K et al. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996 312(7024): 169-72.
54. Islam S, Mekhloufi F Paul JM et al. Characteristics of clometacin-induced hepatitis with special reference to the presence of anti-actin cable antibodies. Autoimmunity 1989 2(3): 213-21.
55. Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci 1993 38(4): 744-51.
56. Bernard PH, Lamouliatte H, Le Bail B et al. Chronic active hepatitis associated with antinuclear antibodies induced by fenofibrate. Gastroenterol Clin Biol 1994 18(11): 1048-9.
57. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis 2009 29(4): 412-22.
58. Kamiyama T, Nouchi T, Kojima S et al. Autoimmune hepatitis triggered byadministration of an herbal medicine. Am J Gastroenterol 1997 92(4): 703-4.
59. Kancherla D, Gajendran M, Vallabhaneni P, Vipperla K. Metronidazole induced liver injury: a rare immune mediated drug reaction. Case Rep Gastrointest Med 2013 2013: 568193.
60. Cerulli J, Grabe DW, Gauthier I, Malone M, McGoldrick MD. Chromium picolinate toxicity. Ann Pharmacother 1998 32(4): 428-31.
61. Licata A, Maida M, Cabibi D et al. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. Dig Liver Dis 2014 (Dec); 46(12): 1116-20.
62. Suzuki A, Brunt EM, Kleiner DE et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology 2011 (Sep 2); 54 (3): 931-9.
63. Zhang X, Ouyang J, Thung SN. Histopathologic manifestations of drug-induced hepatotoxicity. Clin Liver Dis 2013 (Nov); 17 (4): 547-64.
64. Dufour JF, Zimmerman M, Reichen J. Severe autoimmune hepatitis in patients with spontaneous recovery of a flare. J Hepatol 2002 37(6): 748-52.
65. Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int 2009 29(6): 816-23.
66. Weiler-Normann C, Schramm C. Drug induced liver injury and its relationship to autoimmune hepatitis. J Hepatol 2011 (Oct); 55 (4): 747-9.
67. Björnsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009 50(3): 511-7.
68. Lucena MI, Kaplowitz N, Hallal H et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol 2011 55(4): 820-7.
69. Sugimoto K, Ito T, Yamamoto N, Shiraki K. Seven cases of autoimmune hepatitis that developed after drug-induced liver injury. Hepatology 2011 54(5): 1892-3.